Sonrotoclax/Zanubrutinib Combo Elicits Deep Responses for Untreated CLL/SLL
For patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.
Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors
Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.
Individually Optimizing Cancer Outcomes Through a Mission of Survivorship Care
A panel of cancer survivorship experts outline major areas of focus and care models for improving outcomes among pediatric and adult survivors of cancer.
Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer
A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.
Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma
Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.
General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma
Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.
